| Erin Lindsey-trout, RN, CNM | |
|
1108 E Mulberry St Ste A, Angleton Rmchp, Angleton, TX 77515-3955 | |
| (979) 849-0692 | |
| Not Available |
| Full Name | Erin Lindsey-trout |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 1108 E Mulberry St Ste A, Angleton, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770980617 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | AP126976 (Texas) | Primary |
| 163WM0102X | Registered Nurse - Maternal Newborn | 768375 (Texas) | Secondary |
| Entity Name | Utmb Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241146 PECOS PAC ID: 3375456734 Enrollment ID: O20031112000438 |
News Archive
Scientists at Case Western Reserve University have used Artificial Intelligence (AI) to identify new biomarkers for breast cancer that can predict whether the cancer will return after treatment-;and which can be identified from routinely acquired tissue biopsy samples of early-stage breast cancer.
Molecules that bind and illuminate proteins specific to tumor cells are key to detecting cancer as early as possible. The cyclooxygenase-2 enzyme is just such a protein, as the concentration of COX-2 is greater in cancer cells than in adjacent normal tissues.
A new study has revealed a technology how to cover biodegradable implants with a human skeleton similar mineral.
Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer.
Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify patients with prostate cancer with a low risk of spreading, which might determine the best course of treatment for the patient.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Lindsey-trout, RN, CNM 301 University Blvd, Rmchp, Galveston, TX 77555-0519 Ph: () - | Erin Lindsey-trout, RN, CNM 1108 E Mulberry St Ste A, Angleton Rmchp, Angleton, TX 77515-3955 Ph: (979) 849-0692 |
News Archive
Scientists at Case Western Reserve University have used Artificial Intelligence (AI) to identify new biomarkers for breast cancer that can predict whether the cancer will return after treatment-;and which can be identified from routinely acquired tissue biopsy samples of early-stage breast cancer.
Molecules that bind and illuminate proteins specific to tumor cells are key to detecting cancer as early as possible. The cyclooxygenase-2 enzyme is just such a protein, as the concentration of COX-2 is greater in cancer cells than in adjacent normal tissues.
A new study has revealed a technology how to cover biodegradable implants with a human skeleton similar mineral.
Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer.
Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify patients with prostate cancer with a low risk of spreading, which might determine the best course of treatment for the patient.
› Verified 3 days ago
Ruth Elizabeth Soulsby-monroy, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1108a E Mulberry St, Angleton, TX 77515 Phone: 979-849-9740 Fax: 979-849-1094 |